AstraZeneca strikes $272M deal for Ardelyx kidney drug

Deal-hungry AstraZeneca ($AZN) nabbed a potential treatment for chronic kidney disease in a $272 million deal with Ardelyx. Under the new partnership, Adelyx gets $35 million up front, plus up to $237.5 million in milestones, provided the RX5791 drug makes it to market. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.